POU2AF1

Across TCGA pan-cancer cohorts, POU2AF1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated POU2AF1 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher POU2AF1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated POU2AF1 expression acts as an unfavorable survival marker.

ACC, KIRP, and COAD are the cancer types where POU2AF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
KIRP	DFS	Median	II,III,IV	0.038	0.783	<.001	15	view →
COAD	DFS	Median	All	0.140	0.781	<.001	15	view →
THCA	DFS	Median	All	0.133	0.842	.001	12	view →
BLCA	OS	Median	All	0.227	0.620	.014	6	view →
SKCM	OS	Median	All	0.390	0.783	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

POU2AF1–ACC (DFS)

Open the ACC breakdown →